Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM.

Lancet Oncol. 2019 Jun 3. pii: S1470-2045(19)30331-6. doi: 10.1016/S1470-2045(19)30331-6. [Epub ahead of print]

PMID:
31171444
2.

LNK suppresses interferon signaling in melanoma.

Ding LW, Sun QY, Edwards JJ, Fernández LT, Ran XB, Zhou SQ, Scolyer RA, Wilmott JS, Thompson JF, Doan N, Said JW, Venkatachalam N, Xiao JF, Loh XY, Pein M, Xu L, Mullins DW, Yang H, Lin DC, Koeffler HP.

Nat Commun. 2019 May 20;10(1):2230. doi: 10.1038/s41467-019-09711-y.

3.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.

Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Oncotarget. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29.

4.

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials.

Edwards J, Tasker A, Pires da Silva I, Quek C, Batten M, Ferguson A, Allen R, Allanson B, Saw RPM, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA.

Clin Cancer Res. 2019 Jun 1;25(11):3247-3258. doi: 10.1158/1078-0432.CCR-18-4011. Epub 2019 Feb 18.

PMID:
30777877
5.

Molecular Genomic Profiling of Melanocytic Nevi.

Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS.

J Invest Dermatol. 2019 Feb 14. pii: S0022-202X(19)30118-6. doi: 10.1016/j.jid.2018.12.033. [Epub ahead of print]

PMID:
30772300
6.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS.

Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003.

PMID:
30753825
7.

Author Correction: Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Feb;566(7745):E10. doi: 10.1038/s41586-019-0958-0.

PMID:
30742076
8.

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, Madore J, Edwards J, Carlino MS, Guminski A, Saw RPM, Thompson JF, Ferguson PM, Palendira U, Menzies AM, Long GV, Scolyer RA, Wilmott JS.

Oncoimmunology. 2018 Oct 31;8(2):e1537581. doi: 10.1080/2162402X.2018.1537581. eCollection 2019.

PMID:
30713793
9.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

10.

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.

Pires da Silva I, Wang KYX, Wilmott JS, Holst J, Carlino MS, Park JJ, Quek C, Wongchenko M, Yan Y, Mann G, Johnson DB, McQuade JL, Rai R, Kefford RF, Rizos H, Scolyer RA, Yang JYH, Long GV, Menzies AM.

Clin Cancer Res. 2019 Feb 15;25(4):1272-1279. doi: 10.1158/1078-0432.CCR-18-1680. Epub 2019 Jan 10.

PMID:
30630828
11.

Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Jan;565(7739):366-371. doi: 10.1038/s41586-018-0812-9. Epub 2018 Dec 31. Erratum in: Nature. 2019 Feb;566(7745):E10.

PMID:
30598548
12.

Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.

Gide TN, Allanson BM, Menzies AM, Ferguson PM, Madore J, Saw RPM, Thompson JF, Long GV, Wilmott JS, Scolyer RA.

Histopathology. 2019 May;74(6):817-828. doi: 10.1111/his.13814.

PMID:
30589949
13.

RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.

Guo D, Lui GYL, Lai SL, Wilmott JS, Tikoo S, Jackett LA, Quek C, Brown DL, Sharp DM, Kwan RYQ, Chacon D, Wong JH, Beck D, van Geldermalsen M, Holst J, Thompson JF, Mann GJ, Scolyer RA, Stow JL, Weninger W, Haass NK, Beaumont KA.

Int J Cancer. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3.

PMID:
30556600
14.

Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.

Dodds TJ, Wilmott JS, Jackett LA, Lo SN, Long GV, Thompson JF, Scolyer RA.

Pathology. 2019 Jan;51(1):39-45. doi: 10.1016/j.pathol.2018.09.060. Epub 2018 Nov 26.

PMID:
30497801
15.

Epigenetic profiling for the molecular classification of metastatic brain tumors.

Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, Salomon MP, Barkhoudarian G, Jalas JR, Wilmott JS, Hothi P, Wang X, Takasumi Y, Buckland ME, Thompson JF, Long GV, Cobbs CS, Shmulevich I, Kelly DF, Scolyer RA, Hoon DSB, Marzese DM.

Nat Commun. 2018 Nov 6;9(1):4627. doi: 10.1038/s41467-018-06715-y.

16.

Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features.

Salomon MP, Orozco JIJ, Wilmott JS, Hothi P, Manughian-Peter AO, Cobbs CS, Scolyer RA, Hoon DSB, Marzese DM.

Sci Data. 2018 Nov 6;5:180245. doi: 10.1038/sdata.2018.245.

17.

bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays.

Wang KYX, Menzies AM, Silva IP, Wilmott JS, Yan Y, Wongchenko M, Kefford RF, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH.

Bioinformatics. 2018 Sep 12. doi: 10.1093/bioinformatics/bty783. [Epub ahead of print]

PMID:
30215668
18.

Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.

Wilmott JS, Hayward NK, Mann GJ, Scolyer RA.

Melanoma Manag. 2017 Sep;4(3):147-149. doi: 10.2217/mmt-2017-0008. Epub 2017 Jul 26. No abstract available.

19.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21.

PMID:
30178487
20.

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann GJ, Long GV, Scolyer RA, Molloy MP.

Br J Cancer. 2018 Sep;119(6):713-723. doi: 10.1038/s41416-018-0227-2. Epub 2018 Aug 17.

PMID:
30116025
21.

Differences in LC3B expression and prognostic implications in oropharyngeal and oral cavity squamous cell carcinoma patients.

Lai K, Matthews S, Wilmott JS, Killingsworth MC, Yong JL, Caixeiro NJ, Wykes J, Samakeh A, Forstner D, Lee M, McGuinness J, Niles N, Hong A, Ebrahimi A, Lee CS.

BMC Cancer. 2018 Jun 1;18(1):624. doi: 10.1186/s12885-018-4536-x.

22.

Melanoma protective antitumor immunity activated by catalytic DNA.

Cai H, Cho EA, Li Y, Sockler J, Parish CR, Chong BH, Edwards J, Dodds TJ, Ferguson PM, Wilmott JS, Scolyer RA, Halliday GM, Khachigian LM.

Oncogene. 2018 Sep;37(37):5115-5126. doi: 10.1038/s41388-018-0306-0. Epub 2018 May 29.

PMID:
29844573
23.

Telomere sequence content can be used to determine ALT activity in tumours.

Lee M, Teber ET, Holmes O, Nones K, Patch AM, Dagg RA, Lau LMS, Lee JH, Napier CE, Arthur JW, Grimmond SM, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Wilmott JS, Reddel RR, Pearson JV, Waddell N, Pickett HA.

Nucleic Acids Res. 2018 Jun 1;46(10):4903-4918. doi: 10.1093/nar/gky297.

24.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.

Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

PMID:
29602646
25.

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment.

Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton WJ, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U.

Clin Cancer Res. 2018 Jul 1;24(13):3036-3045. doi: 10.1158/1078-0432.CCR-17-2257. Epub 2018 Mar 29.

PMID:
29599411
26.

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2018 May 1;142(9):1926-1937. doi: 10.1002/ijc.31199. Epub 2017 Dec 20.

27.

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.

Gide TN, Wilmott JS, Scolyer RA, Long GV.

Clin Cancer Res. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10. Review.

28.

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

Holtkamp LHJ, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):660. doi: 10.1245/s10434-017-6170-2. Epub 2017 Oct 27. No abstract available.

PMID:
29079922
29.

Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L.

Cancer Res. 2017 Nov 15;77(22):6226-6239. doi: 10.1158/0008-5472.CAN-17-1965. Epub 2017 Sep 25.

30.

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA.

Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.

31.

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.

Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.

Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. doi: 10.1158/1078-0432.CCR-16-1688. Epub 2017 Jul 19.

32.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

33.

The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.

Wilmott JS, Rizos H, Scolyer RA, Long GV.

Clin Cancer Res. 2017 Jun 15;23(12):2921-2923. doi: 10.1158/1078-0432.CCR-17-0669. Epub 2017 May 3.

34.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
35.

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS.

Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9.

36.

Mutation load in melanoma is affected by MC1R genotype.

Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, Scolyer RA, Mann GJ, Hayward NK.

Pigment Cell Melanoma Res. 2017 Mar;30(2):255-258. doi: 10.1111/pcmr.12571. Epub 2017 Mar 7.

PMID:
28024115
37.

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A.

Sci Transl Med. 2016 Dec 14;8(369):369ra177.

PMID:
27974665
38.

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.

Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B.

Pigment Cell Melanoma Res. 2016 Jul;29(4):444-52. doi: 10.1111/pcmr.12489.

PMID:
27166757
39.

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.

PMID:
27151331
40.

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA.

Pathology. 2016 Apr;48(3):261-6. doi: 10.1016/j.pathol.2016.01.001. Epub 2016 Mar 9.

PMID:
27020503
41.

Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.

Kakavand H, Wilmott JS, Long GV, Scolyer RA.

Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20. Review.

PMID:
27020392
42.

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.

Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Clin Cancer Res. 2016 Aug 1;22(15):3915-23. doi: 10.1158/1078-0432.CCR-15-1714. Epub 2016 Mar 9.

43.

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, Blokx WA, Massi D, Thompson JF, Scolyer RA, van Baren N, van den Oord JJ.

Mod Pathol. 2016 Apr;29(4):347-58. doi: 10.1038/modpathol.2016.28. Epub 2016 Feb 12.

44.

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW.

Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.

45.

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, Kennedy CW, Gluch L, Carmalt H, Mak C, Warrier S, Gee HE, Chan C, McLean A, Walker E, McNeil CM, Beith JM, Swarbrick A, Scolyer RA, O'Toole SA.

Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.

PMID:
26588661
46.

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.

Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, Croft A, Hondermarck H, Scolyer RA, Jiang CC, Zhang XD.

Oncotarget. 2015 Nov 24;6(37):39891-907. doi: 10.18632/oncotarget.5359.

47.

Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes.

Wilmott JS, Field MA, Johansson PA, Kakavand H, Shang P, De Paoli-Iseppi R, Vilain RE, Pupo GM, Tembe V, Jakrot V, Shang CA, Cebon J, Shackleton M, Fitzgerald A, Thompson JF, Hayward NK, Mann GJ, Scolyer RA.

Pathology. 2015 Dec;47(7):683-93. doi: 10.1097/PAT.0000000000000324. Erratum in: Pathology. 2016 Jan;48(1):104.

PMID:
26517638
48.

Recurrent inactivating RASA2 mutations in melanoma.

Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y.

Nat Genet. 2015 Dec;47(12):1408-10. doi: 10.1038/ng.3427. Epub 2015 Oct 26.

49.

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA.

Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25.

50.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

Supplemental Content

Loading ...
Support Center